Dear teachers!  For this lecture, we have invited Álvaro Aytes. The title of the presentation is: Nsd2 drives castration resistance and response to Ezh2 inhibition in prostate cancer.

Dr. Álvaro Aytes is Principal Investigator at the Catalan Institute of Oncology and Bellvitge Biomedical Research Institute (IDIBELL), where he leads the Program Against Cancer Therapy Resistance and the Prostate Cancer Group. His research focuses on understanding molecular and epigenetic mechanisms of resistance in advanced prostate cancer, particularly castration-resistant forms.

After earning his Ph.D. from the University of Barcelona in 2008, Dr. Aytes trained at Columbia University (New York) as a Marie Curie Fellow and later as an Associate Research Scientist. His work has revealed key drivers of therapy resistance, such as NSD2 and the FOXM1/CENPF axis, and has shaped new therapeutic strategies through systems biology and preclinical models.

Dr. Aytes has authored over 25 peer-reviewed publications in top-tier journals including Cell, Cancer Cell, and Nature Communications, with more than 2,200 citations. He has received prestigious awards such as the Miguel Servet Fellowships, BBVA Leonardo Grant, and EAU Career Development Fellowship.

An active mentor and educator, he teaches oncology-related courses at the University of Barcelona and serves in leadership roles in European research consortia. Committed to science outreach and patient advocacy, Dr. Aytes bridges basic cancer research and clinical impact with a strong emphasis on translational innovation.